C
Caroline Laverdière
Researcher at Université de Montréal
Publications - 176
Citations - 5214
Caroline Laverdière is an academic researcher from Université de Montréal. The author has contributed to research in topics: Childhood Acute Lymphoblastic Leukemia & Population. The author has an hindex of 33, co-authored 153 publications receiving 4287 citations. Previous affiliations of Caroline Laverdière include Centre Hospitalier Universitaire Sainte-Justine & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985―2000)
Lewis B. Silverman,Kristen E. Stevenson,Jane E. O'Brien,Barbara L. Asselin,Ronald D. Barr,Luis A. Clavell,Peter D. Cole,Kara M. Kelly,Caroline Laverdière,Bruno Michon,Marshall A. Schorin,Cindy L. Schwartz,Eileen Whyte O’Holleran,Donna Neuberg,Harvey J. Cohen,Stephen E. Sallan +15 more
TL;DR: Results of randomized studies revealed that dexrazoxane prevented acute cardiac injury without adversely affecting EFS or OS in high-risk (HR) patients, and frequently dosed intrathecal chemotherapy was an effective substitute for cranial radiation in standard-risk patients.
Journal ArticleDOI
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes
Steven E. Lipshultz,Tracie L. Miller,Rebecca E. Scully,Stuart R. Lipsitz,Nader Rifai,Lewis B. Silverman,Steven D. Colan,Donna Neuberg,Suzanne E. Dahlberg,Jacqueline M. Henkel,Barbara L. Asselin,Uma H. Athale,Luis A. Clavell,Caroline Laverdière,Bruno Michon,Marshall A. Schorin,Stephen E. Sallan +16 more
TL;DR: Cardiac troponin T and NT-proBNP may hold promise as biomarkers of cardiotoxicity in children with high-risk ALL, and definitive validation studies are required to fully establish their range of clinical utility.
Journal ArticleDOI
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
Lynda M. Vrooman,Kristen E. Stevenson,Jeffrey G. Supko,Jane E. O'Brien,Suzanne E. Dahlberg,Barbara L. Asselin,Uma H. Athale,Luis A. Clavell,Kara M. Kelly,Jeffery L. Kutok,Caroline Laverdière,Steven E. Lipshultz,Bruno Michon,Marshall A. Schorin,Mary V. Relling,Harvey J. Cohen,Donna Neuberg,Stephen E. Sallan,Lewis B. Silverman +18 more
TL;DR: Monitoring nadir serum asparaginase activity (NSAA) during treatment with EC-Asnase may be an effective strategy to improve outcome in pediatric ALL.
Journal ArticleDOI
Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.
TL;DR: A G(80)A polymorphism has been described in the reduced folate carrier gene (RFC1), which encodes the major MTX transporter, and both MTX plasma levels and childhood ALL outcome were assessed.
Journal ArticleDOI
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
Andrew E. Place,Andrew E. Place,Kristen E. Stevenson,Lynda M. Vrooman,Lynda M. Vrooman,Marian H. Harris,Sarah K. Hunt,Jane E. O'Brien,Jeffrey G. Supko,Barbara L. Asselin,Uma H. Athale,Luis A. Clavell,Peter D. Cole,Kara M. Kelly,Caroline Laverdière,Jean-Marie Leclerc,Bruno Michon,Marshall A. Schorin,Jennifer J.G. Welch,Steven E. Lipshultz,Jeffery L. Kutok,Traci M. Blonquist,Donna Neuberg,Stephen E. Sallan,Stephen E. Sallan,Lewis B. Silverman,Lewis B. Silverman +26 more
TL;DR: The aim of the Dana-Farber Cancer Institute Acute Lymphoblastic Leukaemia Consortium Protocol 05-001 was to compare the relative toxicity and efficacy of intravenous PEG-asparaginase and intramuscular native E colil-as paraginase in children with newly diagnosed acute lymphoblastic leukaemia.